DB:5D8

Stock Analysis Report

Executive Summary

DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from bacteria for the health, nutrition, and cosmetics industries worldwide.

Snowflake

Fundamentals

Slightly overvalued with limited growth.

Share Price & News

How has Deinove's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

30.5%

5D8

3.9%

DE Chemicals

2.4%

DE Market


1 Year Return

-66.9%

5D8

-3.3%

DE Chemicals

4.9%

DE Market

Return vs Industry: 5D8 underperformed the German Chemicals industry which returned -3.3% over the past year.

Return vs Market: 5D8 underperformed the German Market which returned 4.9% over the past year.


Shareholder returns

5D8IndustryMarket
7 Day30.5%3.9%2.4%
30 Day-5.0%4.1%2.3%
90 Day-30.2%2.8%2.7%
1 Year-66.9%-66.9%0.5%-3.3%8.2%4.9%
3 Year-64.9%-64.9%-1.9%-11.2%18.3%8.0%
5 Year-89.2%-89.6%25.6%6.4%44.2%24.6%

Price Volatility Vs. Market

How volatile is Deinove's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Deinove undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 5D8 (€0.75) is trading below our estimate of fair value (€19.17)

Significantly Below Fair Value: 5D8 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 5D8 is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.

PE vs Market: 5D8 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 5D8's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 5D8 has negative assets, so we can't compare its PB Ratio to the DE Chemicals industry average.


Next Steps

Future Growth

How is Deinove forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-2.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 5D8 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 5D8 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 5D8 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 5D8's revenue (79% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 5D8's revenue (79% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 5D8's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Deinove performed over the past 5 years?

-9.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 5D8 is unprofitable, and losses have increased over the past 5 years at a rate of -9.6% per year.

Accelerating Growth: Unable to compare 5D8's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5D8 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-5.5%).


Return on Equity

High ROE: 5D8's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: 5D8 is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: 5D8 is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Deinove's financial position?


Financial Position Analysis

Short Term Liabilities: 5D8 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 5D8 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 5D8 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 5D8's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 5D8 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 5D8 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 5D8 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 5D8 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -23.1% each year


Next Steps

Dividend

What is Deinove's current dividend yield, its reliability and sustainability?

189.87%

Forecast Dividend Yield


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage4.0%forecastin3Years189.9%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate 5D8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 5D8's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 5D8's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 5D8's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 5D8's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Deinove's salary, the management and board of directors tenure and is there insider trading?

4.0yrs

Average management tenure


CEO

Emmanuel Petiot 0

7.3yrs

Tenure

0

Mr. Emmanuel Petiot has been the Chief Executive Officer of Deinove SA since June 12, 2012. Mr. Petiot served as a Director of Sales of Novozymes North America Inc. For 9 years, he had a brilliant career i ...


Management Age and Tenure

4.0yrs

Average Tenure

Experienced Management: 5D8's management team is considered experienced (4 years average tenure).


Board Age and Tenure

7.8yrs

Average Tenure

61yo

Average Age

Experienced Board: 5D8's board of directors are considered experienced (7.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Julien Coste

    Director of Finance & Administration

    • Tenure: 0yrs
  • Miroslav Radman

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Emmanuel Petiot

    Chief Executive Officer

    • Tenure: 7.3yrs
  • Coralie Martin

    Head of Marketing

    • Tenure: 2.3yrs
  • Marie Bézenger

    Director of Operations

    • Tenure: 4yrs
  • Sébastien Enault

    Head of Business Development

    • Tenure: 0yrs
  • Johane Rinaldi

    Head of Human Resources

    • Tenure: 0yrs

Board Members

  • Philippe Pouletty (61yo)

    Director

    • Tenure: 9.8yrs
  • Charles Woler (69yo)

    Independent Chairman of the Board

    • Tenure: 2.8yrs
  • Christian Pierret

    Director

    • Tenure: 9.8yrs
  • Jacques Biton (61yo)

    Vice President of the Scientific Advisory Board

    • Tenure: 0yrs
  • Miroslav Radman

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Gérard Goma

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Ivan Matic

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jacqueline Lecourtier

    President of the Scientific Advisory Board

    • Tenure: 5.9yrs
  • Armel Guyonvarch

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • François Kepes

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Deinove SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Deinove SA
  • Ticker: 5D8
  • Exchange: DB
  • Founded: 2006
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: €13.057m
  • Shares outstanding: 16.53m
  • Website: https://www.deinove.com

Number of Employees


Location

  • Deinove SA
  • Cap Sigma
  • 1682 rue de la Valsière
  • Grabels
  • Languedoc-Roussillon
  • 34790
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALDEIENXTPA (Euronext Paris)YesCommon SharesFREURApr 2010
5D8DB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2010

Biography

DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from bacteria for the health, nutrition, and cosmetics industries worldwide. It focuses on antibiotics against resista ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 21:06
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.